Threshold's Drug Trial Suspended

The Food and Drug Administration partially suspended Threshold Pharmaceuticals Inc.'s (THLD) Phase 3 clinical trial of the prostate treatment TH-070 due to liver complications. The stock price plummeted $10.56 to close at $3.44.